Oliveira, Luis M. A. http://orcid.org/0000-0002-2958-181X
Gasser, Thomas
Edwards, Robert
Zweckstetter, Markus http://orcid.org/0000-0002-2536-6581
Melki, Ronald http://orcid.org/0000-0003-0000-7096
Stefanis, Leonidas http://orcid.org/0000-0003-3569-8990
Lashuel, Hilal A. http://orcid.org/0000-0001-7682-8320
Sulzer, David http://orcid.org/0000-0001-7632-0439
Vekrellis, Kostas
Halliday, Glenda M. http://orcid.org/0000-0003-0422-8398
Tomlinson, Julianna J.
Schlossmacher, Michael http://orcid.org/0000-0002-0394-0300
Jensen, Poul Henning
Schulze-Hentrich, Julia
Riess, Olaf
Hirst, Warren D. http://orcid.org/0000-0003-0389-8891
El-Agnaf, Omar
Mollenhauer, Brit
Lansbury, Peter
Outeiro, Tiago F. http://orcid.org/0000-0003-1679-1727
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Michael J. Fox Foundation for Parkinson’s Research
Michael J. Fox Foundation for Parkinson’s Research
Article History
Received: 24 December 2020
Accepted: 14 May 2021
First Online: 26 July 2021
Competing interests
: D.S. is Chief Editor of the journal, but will not handle the manuscript. W.H. is employee and stockholder of Biogen. The employer of M. Schlossmacher and J. Tomlinson (Ottawa Hospital Research Institute) has received licensing fees from BioLegend Inc (formerly Covance; Dedham, MA.) between 2011 and 2020 for the commercialization of immunological reagents to quantify aSyn. B.M. is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson’s Research. P.L. is and employee of Bial Biotech and an SAB member of Lucy therapeutics, Amathus Therapeutics and Triplet Therapeutics. All other authors have no competing interests to declare.